Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS

주식 순위 #17345
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
주가
$8.16
마지막 동기화: 2025-06-26
시가총액
$234.57M
변동 (1일)
0.00%
변동 (1년)
-56.96%
국가
US
거래 Regulus Therapeutics Inc. (RGLS)

카테고리

Healthcare
Regulus Therapeutics Inc. (RGLS)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 47.29
Regulus Therapeutics Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 47.29입니다. 2022년 말 기준 P/B 비율은 2.90였습니다.
Regulus Therapeutics Inc.의 P/B 비율 기록 (2002 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
2026 (TTM) 47.29 88.70%
2023 25.06 763.59%
2022 2.90 -35.79%
2021 4.52 -8.11%
2020 4.92 -51.71%
2019 10.19 79.87%
2018 5.66 -19.96%
2017 7.08 11.24%
2016 6.36 -8.92%
2015 6.98 11.58%
2014 6.26 17.25%
2013 5.34 -42.86%
2012 9.34 -75.23%
2011 37.72 -1.55%
2010 38.31 0.97%
2009 37.94 -8.24%
2008 41.34 -2.27%
2007 42.30 -30.66%
2006 61.01 -34.31%
2005 92.88 -23.51%
2004 121.42 -15.67%
2003 143.98 -35.74%
2002 224.08 0.00%
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.251 -86.78%
US
13.2547 -71.97%
US
4.208 -91.10%
AU
- -
CH
6.1824 -86.93%
NL